Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Treatment and Prognosis of Pulmonary Embolism
share announcement

Treatment and Prognosis of Pulmonary Embolism

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Vascular Medicine".

Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 7097

Special Issue Editor

Prof. Dr. Drahomir Aujesky

E-Mail Website
Guest Editor
Division of General Internal Medicine, University of Bern, Bern, Switzerland
Interests: venous thromboembolism; prevention; diagnosis; treatment; prognosis

Special Issue Information

Dear Colleagues,

Acute pulmonary embolism (PE) is most often caused when deep vein thrombi in the leg break off the vein wall and travel to the pulmonary arteries. Depending on the thromboembolic burden and patient factors, the clinical spectrum of PE varies widely and ranges from asymptomatic cases to massive PE with right ventricular failure, hemodynamic collapse, and sudden death. Besides the risk of death, venous thromboembolism (VTE) recurrence, the occurrence of the post-PE syndrome, and PE-related quality of life/functional status are further outcomes that matter to patients with PE.

The standard treatment for PE is anticoagulant therapy for at least 3 months. While anticoagulant treatment reduces the risk of recurrent VTE by 80-90%, anticoagulation carries a short-term major bleeding risk of up to 4%. Major bleeding is potentially life-threatening, with a case-fatality of 11%, and 10% of patients with major bleeding suffer intracranial hemorrhage. Given the burden and impact of bleeding complications, the benefits of anticoagulation need to be carefully weighed against its risks.

The prognosis of PE has a direct impact on clinical management decisions, including the initial site of treatment (home, hospital, ICU), treatment intensity (no anticoagulation, anticoagulant therapy, thrombolysis) as well as treatment duration. Over the last two decades, several prognostic tools, such as clinical prognostic models, right-ventricular function imaging, and biomarkers have been validated and introduced to clinical practice. Despite these developments, the optimal prognostic strategy for PE is still debated. This Special Issue of the Journal of Clinical Medicine will focus on therapeutic and prognostic aspects of PE management.

Prof. Dr. Drahomir Aujesky
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pulmonary embolism
  • treatment
  • prognosis

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

8 pages, 665 KiB  
Article
A New Experimental Porcine Model of Venous Thromboembolism
by Leszek Gromadziński, Agnieszka Skowrońska, Piotr Holak, Michał Smoliński, Ewa Lepiarczyk, Anna Żurada, Mariusz Krzysztof Majewski, Mariusz Tomasz Skowroński and Marta Majewska
J. Clin. Med. 2021, 10(9), 1862; https://doi.org/10.3390/jcm10091862 - 25 Apr 2021
Cited by 7 | Viewed by 2743
Abstract
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a severe disease affecting the human venous system, accompanied by high morbidity and mortality rates. The aim of the study was to establish a new porcine VTE model based on [...] Read more.
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a severe disease affecting the human venous system, accompanied by high morbidity and mortality rates. The aim of the study was to establish a new porcine VTE model based on the formation of the thrombus in vivo. The study was performed on 10 castrated male pigs: thrombus was formed in each closed femoral vein and then successfully released from the right femoral vein into the circulation of animals. In six pigs PE was confirmed via both computed tomography pulmonary angiography and an autopsy. Our research presents a novel experimental porcine model of VTE that involves inducing DVT and PE in the same animal in vivo, making it suitable for advanced clinical research and testing of future therapies. Full article
(This article belongs to the Special Issue Treatment and Prognosis of Pulmonary Embolism)
►▼ Show Figures

Figure 1

8 pages, 639 KiB  
Article
The Influence of Gender in The Prognostic Impact of Diabetes mellitus in acute Pulmonary Embolism
by Diana Oliveira, Teresa Brito, Catarina Elias, Marta Carreira, Mariana Serino, Inês Guerreiro, Helena Magalhães, Sara Coelho, Sara Ferreira, Emanuel Araújo, Ana Ribeiro and Patrícia Lourenço
J. Clin. Med. 2020, 9(11), 3511; https://doi.org/10.3390/jcm9113511 - 30 Oct 2020
Cited by 3 | Viewed by 1494
Abstract
Diabetes mellitus (DM) predicts ominous outcomes in acute pulmonary embolism (PE). The influence of gender on the prognostic impact of DM in PE is unknown. We did a retrospective analysis of a cohort of patients hospitalized with PE between 2006 and 2013. The [...] Read more.
Diabetes mellitus (DM) predicts ominous outcomes in acute pulmonary embolism (PE). The influence of gender on the prognostic impact of DM in PE is unknown. We did a retrospective analysis of a cohort of patients hospitalized with PE between 2006 and 2013. The exclusion criteria were age <18, non-pulmonary veins thromboembolism, recurrent PE, chronic thromboembolic pulmonary hypertension, no radiologic confirmation of PE, and active neoplasia. The primary endpoint was all-cause mortality. The follow-up was from diagnosis until October 2017. We assessed the prognostic impact of DM using a multivariate Cox regression analysis. The analysis was stratified according to gender. The interaction between gender and DM in the outcome of patients with PE was tested. We studied 577 PE patients (median age 65 years, 36.9% men, 19.8% diabetic). The genders were similar regarding the prevalence of DM, the extension and location of PE, and the thrombolytic therapy or brain natriuretic peptide (BNP) value. Diabetics presented higher all-cause mortality (Hazard ratio (HR) = 2.33 (95% confidence Interval (CI) 1.513.61)) when compared with non-diabetics. However, when analysis was stratified according to gender, DM was independently associated with a worse prognosis only in women (HR = 2.31 (95% CI 1.453.65)), while in men the HR was 1.10 (95% CI 0.592.04). The interaction between gender and DM was significant (p = 0.04). Gender influences the prognostic impact of DM in acute PE. Diabetic women with PE have twice the long-term mortality risk, while DM is not mortality-associated in men. Full article
(This article belongs to the Special Issue Treatment and Prognosis of Pulmonary Embolism)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 269 KiB  
Review
Venous Thromboembolic Disease in Chronic Inflammatory Lung Diseases: Knowns and Unknowns
by George Keramidas, Konstantinos I. Gourgoulianis and Ourania S. Kotsiou
J. Clin. Med. 2021, 10(10), 2061; https://doi.org/10.3390/jcm10102061 - 11 May 2021
Cited by 11 | Viewed by 2430
Abstract
Persistent inflammation within the respiratory tract underlies the pathogenesis of numerous chronic pulmonary diseases. There is evidence supporting that chronic lung diseases are associated with a higher risk of venous thromboembolism (VTE). However, the relationship between lung diseases and/or lung function with VTE [...] Read more.
Persistent inflammation within the respiratory tract underlies the pathogenesis of numerous chronic pulmonary diseases. There is evidence supporting that chronic lung diseases are associated with a higher risk of venous thromboembolism (VTE). However, the relationship between lung diseases and/or lung function with VTE is unclear. Understanding the role of chronic lung inflammation as a predisposing factor for VTE may help determine the optimal management and aid in the development of future preventative strategies. We aimed to provide an overview of the relationship between the most common chronic inflammatory lung diseases and VTE. Asthma, chronic obstructive pulmonary disease, interstitial lung diseases, or tuberculosis increase the VTE risk, especially pulmonary embolism (PE), compared to the general population. However, high suspicion is needed to diagnose a thrombotic event early as the clinical presentation inevitably overlaps with respiratory disorders. PE risk increases with disease severity and exacerbations. Hence, hospitalized patients should be considered for thromboprophylaxis administration. Conversely, all VTE patients should be asked for lung comorbidities before determining anticoagulant therapy duration, as those patients are at increased risk of recurrent PE episodes rather than DVT. Further research is needed to understand the underlying pathophysiology of in-situ thrombosis in those patients. Full article
(This article belongs to the Special Issue Treatment and Prognosis of Pulmonary Embolism)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop